Last updated 3 August 2026 · Originally published 1 February 2020
When you’re trapped in the throes of a head-splitting migraine, you’ll do anything for relief. Countless sufferers have worked through the doctor’s visits, the prescriptions, and anything else with a remote possibility of helping. So when CBD arrived in the wellness aisle promising relief from pain, plenty of people were willing to try it.
For years the honest answer was that nobody really knew. That changed at the end of 2025, when the first proper clinical trial of cannabinoids for acute migraine finally reported. Its results are worth knowing before you spend money — because CBD-dominant cannabis did not beat placebo on the outcomes the trial set out to measure.
At a glance
- In the first randomised trial of its kind, vaporised CBD-dominant cannabis was not better than placebo on the prespecified two-hour outcomes.
- A THC-CBD combination was better than placebo across all three outcomes at two hours, with some benefits remaining at 24 and 48 hours.
- Animal research shows CBD acting on migraine-relevant pathways, but that has not yet translated into demonstrated benefit in people.
- Regular cannabis use for headache may lead to tolerance, and THC-containing products carry side effects.
- CBD can interact with prescription medication. Talk to a doctor or pharmacist before combining them.
Why cannabinoids were investigated at all
The interest is not arbitrary. The endocannabinoid system — the network of receptors and signalling molecules your body already uses to regulate pain — is active in the pathways involved in migraine. A 2018 review in Frontiers in Pharmacology noted that the properties making cannabinoids interesting here include anticonvulsive, analgesic, antiemetic and anti-inflammatory effects.[1]
Animal work has since gone further. A 2023 study in The Journal of Headache and Pain found that CBD reduced trigeminal hyperalgesia in a rat migraine model and lowered levels of CGRP — a signalling molecule central to migraine, and the target of several modern migraine drugs — in the relevant brain regions.[2] A separate 2023 mouse study found CBD prevented pain sensitivity around the eye after CGRP exposure, and produced no sign of the medication overuse headache that can follow repeated triptan use.[3]
That is a biologically plausible signal, and a reason to take the question seriously. It is also, so far, a signal demonstrated in rodents.
The trial that finally tested it
Until recently, every claim about cannabis and migraine rested on animal models, surveys and recollection. In late 2025 a team at the University of California San Diego published the first randomised, double-blind, placebo-controlled trial of cannabis for acute migraine.[4]
The design was strong for this field. Ninety-two adults enrolled and were asked to treat up to four separate migraine attacks — one with vaporised THC-dominant flower, one with CBD-dominant flower, one with a THC-CBD combination, and one with placebo flower containing neither. The treatments were assigned in random order, with at least a week between attacks, and nobody, including the researchers, knew which was which.
The THC 6% + CBD 11% combination beat placebo on pain relief, pain freedom and freedom from the most bothersome symptom at two hours. Pain freedom remained significantly more common at 24 hours, and freedom from the most bothersome symptom at both 24 and 48 hours.
The CBD-dominant flower did not improve the prespecified two-hour outcomes. THC-dominant flower produced a more limited result, improving pain relief but not complete pain freedom or freedom from the most bothersome symptom.
The combination also produced side effects. Participants reported more sleepiness, euphoria, subjective cognitive impairment and feelings of intoxication than with placebo, though generally less than with THC-dominant flower. No serious adverse events occurred.
That is the clearest answer available to the question in this article’s title, and it is not the answer most CBD marketing implies. The most convincing result belonged to the THC-CBD preparation — but the trial does not establish whether CBD enhanced THC’s effect, or whether that particular preparation simply performed best.
What came before
The earlier evidence now reads differently. In a 2017 conference abstract, an Italian team led by Maria Nicolodi reported that a 200 mg daily THC-CBD preparation reduced migraine attacks by 40.4%, compared with 40.1% for amitriptyline, a standard preventive drug.[5] That sounds impressive, but it was reported only as a conference abstract, and the dose was far above a typical consumer serving. Below 100 mg, the dose-finding stage found no benefit at all.
A large 2020 analysis of app data from Washington State University found headache severity fell 47.3% and migraine severity 49.6% after cannabis use, across nearly 20,000 self-reported sessions.[6] It also found increasing doses over time and diminishing relief in the headache sessions, patterns consistent with tolerance — though the decline was less clear in sessions specifically recorded as migraine. No medication overuse headache was detected, which is not the same as ruling it out. The study could not separate CBD from THC, had no control group, and relied on self-report.
So where does that leave CBD on its own?
On thin ground, and honestly so. The mechanism is plausible and demonstrated in animals. The one trial designed to test it in humans found no advantage over placebo on its prespecified outcomes for acute attacks.
Two caveats keep the question open. The trial tested acute treatment — taking something during an attack — and says nothing about whether daily CBD might reduce how often attacks happen. A dedicated trial of CBD for chronic migraine prevention is registered but has not reported, and other registered prevention studies are testing mixed-cannabinoid preparations. And a single trial, however well designed, is a single trial.
What it does settle is the marketing claim. If someone tells you CBD is proven for migraine, they are ahead of the evidence.
The finding points somewhere specific: the preparation that worked contained both THC and CBD. But this should not be read as evidence that an ordinary full-spectrum CBD oil will have the same effect. The trial used four puffs of vaporised flower containing 6% THC and 11% CBD — a different route, cannabinoid exposure and onset from a retail oil containing only trace THC. Our guide to full spectrum, broad spectrum and isolate explains those differences, particularly for anyone subject to drug testing.
Practical considerations
There is no established dose. The trials used vaporised flower or 200 mg cannabinoid combinations — nothing like the 10 to 25 mg per serving common in consumer oils. Anyone using a retail CBD product for migraine is working without an established evidence-based dose, and should say so to their doctor rather than assume a bottle does what a study did.
Check interactions before anything else. CBD can affect the way the body processes some prescription medicines, and other drugs can alter CBD exposure in return. The exact risk depends on what you take, so this is a conversation for a doctor or pharmacist rather than a general interaction checker.
Do not drive or perform safety-sensitive work after taking a THC-containing product.
Watch for tolerance. If the effect fades, escalating the dose is the instinct — and the one most likely to cause problems. Reviews of cannabinoids in headache also flag overuse headache, cognitive effects and dependence as genuine concerns with regular use.[7]
Verify what you are buying. Independent testing repeatedly finds products whose contents differ from their labels. A current, batch-specific lab report is the only way to know what is in a bottle.
None of this is medical advice. Migraine is a neurological condition with effective treatments available, and CBD is not a substitute for proper care. Speak to a doctor before adding it — particularly if you take prescription medication, are pregnant or breastfeeding, or your headaches have changed in pattern or severity.
For the wider picture on what the evidence supports, see our guide to CBD and what the research actually shows, or browse more in Pain & Recovery.
-
References
- Leimuranta P, Khiroug L, Giniatullin R. Emerging role of (endo)cannabinoids in migraine. Frontiers in Pharmacology. 2018;9:420. doi:10.3389/fphar.2018.00420
- Greco R, Francavilla M, Demartini C, et al. Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine. The Journal of Headache and Pain. 2023. PubMed
- Sturaro C, Fakhoury B, Targowska-Duda KM, et al. Preclinical effects of cannabidiol in an experimental model of migraine. Pain. 2023;164(11):2540–2552. doi:10.1097/j.pain.0000000000002960
- Schuster NM, Wallace MS, Marcotte TD, et al. Vaporized cannabis versus placebo for acute migraine: a randomized, double-blind, placebo-controlled crossover trial. Headache. 2026;66(2):365–376. doi:10.1111/head.70025
- Nicolodi M, Sandoval V, Torrini A. Therapeutic use of cannabinoids — dose finding, effects and pilot data of effects in chronic migraine and cluster headache. Presented at the 3rd Congress of the European Academy of Neurology, Amsterdam, 2017. European Journal of Neurology. 2017;24:287.
- Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and long-term effects of cannabis on headache and migraine. The Journal of Pain. 2020;21(5–6):722–730. doi:10.1016/j.jpain.2019.11.001
- Kuruvilla D, et al. Cannabinoids in headache: helpful or harmful? Current Opinion in Neurology. 2025. PubMed
About this article
Expanded in August 2026. This update adds the first randomised controlled trial of cannabinoids for acute migraine, published online in Headache at the end of 2025, which found that CBD-dominant cannabis did not improve the prespecified two-hour outcomes, while a THC-CBD preparation did. It also reports the full results of the studies originally cited and adds the preclinical work on CBD and CGRP signalling.
